Survival Gains Seen With Assignment to Experimental Group in Cancer Trials
Statistically significant survival gains observed for patients with solid tumors assigned to experimental group
Variation ID’d in Risk for Second Primary Cancer After Breast Cancer
Risk for second primary cancer after breast cancer higher for women, especially those who were younger at BC diagnosis
People With Opioid Use Disorder Less Likely to Receive Palliative Care
Difference did not persist after exclusion of people who died suddenly
Cabozantinib Promising for Metastatic Pheochromocytomas, Paragangliomas
Overall response rate was 25.0 percent in phase 2 study involving 17 patients
More Medical Lab Tests Will Soon Face Federal Scrutiny, FDA Says
Cabozantinib Promising for Advanced Adrenocortical Carcinoma
Promising efficacy seen with a manageable safety profile in phase 2 study involving 18 patients
AI Model Reduces False Positives in Screening Mammograms
Other benefits include reduction in unnecessary procedures, patient anxiety, and medical expenses
Exa-Cel Eliminates Vaso-Occlusive Crises in Most Sickle Cell Patients
97 percent of patients were free from vaso-occlusive crises for at least 12 consecutive months
CD7 CAR T-Cell Therapy, Stem-Cell Transplant Beneficial for CD7-Positive Tumors
Six of 10 patients remained in minimal residual disease-negative complete remission after treatment
Mortality Up for Breast Cancer Diagnosed Five to <10 Years After Childbirth
Increased risk for all-cause mortality seen with postpartum young-onset breast cancer in women with germline BRCA pathogenic variants
